U.S. Markets
Eli Lilly (LLY) announces that from January 1st 2027, Zepbound, Mounjaro and Orforglipron will be available through Medicare Part D participating plans
News detail
On cmmi balance model for GLP-1s, patient's cost-sharing will be limited to USD 245/month plus dispensing fee before patients reach their deductible
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
